Barclays PLC 2seventy Bio, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in 2seventy Bio, Inc. stock. As of the latest transaction made, Barclays PLC holds 80,594 shares of TSVT stock, worth $232,916. This represents 0.0% of its overall portfolio holdings.

Number of Shares

80,594

Previous 80,594 -0.0%

Holding current value

$232,916

Previous $380,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	SELL	$3.85 - $5.05 $508,273 - $666,695	-132,019 Reduced 62.09%	80,594 $380,000
Q2 2024 Aug 14, 2024	BUY	$3.6 - $5.79 $165,207 - $265,708	45,891 Added 27.53%	212,613 $817,000
Q1 2024 May 15, 2024	BUY	$3.09 - $6.0 $256,995 - $499,020	83,170 Added 99.54%	166,722 $892,000
Q4 2023 Feb 15, 2024	BUY	$1.57 - $4.58 $63,481 - $185,187	40,434 Added 93.78%	83,552 $356,000
Q3 2023 Nov 07, 2023	SELL	$3.14 - $11.2 $250,132 - $892,192	-79,660 Reduced 64.88%	43,118 $168,000
Q2 2023 Aug 03, 2023	SELL	$8.45 - $12.48 $2.29 Million - $3.39 Million	-271,348 Reduced 68.85%	122,778 $1.24 Million
Q1 2023 May 04, 2023	BUY	$9.21 - $14.98 $2.92 Million - $4.75 Million	317,124 Added 411.84%	394,126 $4.02 Million
Q4 2022 Feb 13, 2023	SELL	$8.57 - $17.0 $54,265 - $107,644	-6,332 Reduced 7.6%	77,002 $722,000
Q3 2022 Nov 03, 2022	BUY	$12.56 - $17.54 $994,726 - $1.39 Million	79,198 Added 1914.85%	83,334 $1.21 Million
Q2 2022 Aug 12, 2022	SELL	$10.55 - $18.81 $11,910 - $21,236	-1,129 Reduced 21.44%	4,136 $55,000
Q1 2022 May 16, 2022	BUY	$11.67 - $26.72 $61,442 - $140,680	5,265 New	5,265 $90,000

Others Institutions Holding TSVT

# of Institutions

126

Shares Held

45.6M

Call Options Held

122K

Put Options Held

19.8K

View Full List

About 2seventy bio, Inc.

Ticker TSVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,873,600
Market Cap $109M
Description
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a col...

More about TSVT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account